Filing Flows › Companies › Indivior Pharmaceuticals › Timeline
Indivior Pharmaceuticals stock timeline
A year of the price with every insider trade, planned sale, earnings report and material 8-K marked
252 sessions+23.6% to $36.28
Indivior Pharmaceuticals (INDV) stock rose 24% over the last 252 sessions, to $36.28. On the way it reported 4 quarters, its insiders filed 3 open-market trades, and the company filed 7 material 8-Ks. Each is marked on the price and listed with what the stock did next.
Each mark, and what followed
| Date | Kind | What | Next session | 5 sessions | 21 sessions |
|---|---|---|---|---|---|
| Oct 29, 2026 | Earnings | Earnings: beat the EPS estimate by 17.2% | +1.4% (+1.8% vs SPY) | — | — |
| Sep 15, 2026 | 8-K | Termination of a material agreement | +0.4% (+0.8% vs SPY) | +5.6% (+3.3% vs SPY) | −0.2% (−2.0% vs SPY) |
| Aug 27, 2026 | Insider buy | Anderson Woodrow D bought $54K | −1.5% (−2.1% vs SPY) | −2.2% (−2.1% vs SPY) | 0.0% (−0.9% vs SPY) |
| Aug 5, 2026 | Insider buy | Anderson Woodrow D bought $54K | +5.9% (+6.1% vs SPY) | +5.1% (+5.2% vs SPY) | −4.0% (−3.3% vs SPY) |
| Aug 3, 2026 | 8-K | Material definitive agreement | −6.8% (−8.2% vs SPY) | −3.0% (−6.5% vs SPY) | −13.6% (−16.2% vs SPY) |
| Aug 3, 2026 | Earnings | Earnings: beat the EPS estimate by 24.8% | −6.8% (−8.2% vs SPY) | −3.0% (−6.5% vs SPY) | −13.6% (−16.2% vs SPY) |
| May 15, 2026 | 8-K | Directors and officers: departures, appointments, pay | −0.6% (−0.5% vs SPY) | +2.1% (+1.2% vs SPY) | +3.3% (+1.8% vs SPY) |
| Apr 30, 2026 | Earnings | Earnings: beat the EPS estimate by 45.5% | +7.4% (+6.4% vs SPY) | +17.3% (+14.2% vs SPY) | +5.3% (−0.8% vs SPY) |
| Mar 17, 2026 | 8-K | Material definitive agreement | −2.6% (−1.2% vs SPY) | −8.4% (−6.0% vs SPY) | +0.6% (−4.2% vs SPY) |
| Mar 6, 2026 | Insider buy | Kingsley Stuart A bought $30K | +0.7% (+2.0% vs SPY) | −3.8% (−1.5% vs SPY) | −5.2% (−2.1% vs SPY) |
| Feb 26, 2026 | Earnings | Earnings: beat the EPS estimate by 21.7% | +0.2% (+0.8% vs SPY) | −4.5% (−3.3% vs SPY) | −11.6% (−4.6% vs SPY) |
| Jan 26, 2026 | 8-K | Material definitive agreement | +1.8% (+1.3% vs SPY) | +7.1% (+6.7% vs SPY) | +0.3% (+0.6% vs SPY) |
| Dec 18, 2025 | 8-K | Directors and officers: departures, appointments, pay | −0.9% (−1.8% vs SPY) | +1.9% (−0.4% vs SPY) | −7.5% (−9.1% vs SPY) |
| Nov 20, 2025 | 8-K | Termination of a material agreement | +3.0% (+2.0% vs SPY) | +5.6% (+1.0% vs SPY) | +13.7% (+8.6% vs SPY) |
Insiders’ record here
In the year on the chart, Indivior Pharmaceuticals' insiders reported 3 open-market buys ($138K) and 0 sales ($0).
Across the whole universe (19,782 scored trades), insider buys beat the market 46% of the time and sales were followed by a lagging stock 61% of the time; buys of $1M or more 39%. Every pattern →
What this kind of 8-K usually did
| Item | 8-Ks | Next session, median | Up next session | 21 sessions, median | Typical size |
|---|---|---|---|---|---|
| 1.02 Termination of a material agreement | 2,368 | 0.0% | 51% | +1.1% | ±1.5% |
| 5.02 Directors and officers: departures, appointments, pay | 39,174 | −0.1% | 48% | +0.7% | ±1.4% |
| 1.01 Material definitive agreement | 23,525 | 0.0% | 51% | +1.0% | ±1.4% |
| 2.03 New debt or off-balance-sheet obligation | 13,268 | 0.0% | 50% | +1.2% | ±1.3% |
| 5.01 Change in control | 233 | +0.2% | 52% | +0.7% | ±2.2% |
Across every company in the move-odds universe, measured from the close before the filing. Every 8-K item ranked →
Report card: every quarter against the estimate → Indivior Pharmaceuticals: every quarter → Live insider trades →
Prices are daily closes; filings and trades are as filed with the SEC (Form 4 within two business days of the trade, 8-K within four of the event). Moves after a mark are the stock's close-to-close change and the same for SPY; they describe the record, not what the next one will do. Not investment advice.